ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next
New York, Jan 13, 2026, 10:45 (EST) — Regular session ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session. The move matters because ImmunityBio is trying to widen the case for ANKTIVA…